SCHEMBL353960

SCHEMBL353960

CN(Cc1nsc(NC(=O)NCc2ccc(Cl)s2)n1)C(=O)C(F)(F)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.36
AR P10275 1/20 0.36
ALDH1A1 P00352 6/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
KMT2A Q03164 5/20 0.35
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 3/20 0.35
RAB9A P51151 2/20 0.33
LMNA P02545 2/20 0.33
NAMPT P43490 1/20 0.33
MAPT P10636 2/20 0.32
TACR1 P25103 1/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MMP3 P08254 1/20 0.32
SCD O00767 1/20 0.32
F2 P00734 1/20 0.32
F10 P00742 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353479 0.86 SCD (0.39) HTTALDH1A1KMT2AKDM4EMEN1
SCHEMBL351570 0.81 ROCK2 (0.47) ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1
SCHEMBL352911 0.80 HSD11B1 (0.42) HTTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL19118740 0.80 ALDH1A1 (0.33) HTTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL353752 0.78 LMNA (0.39) HTTARALDH1A1SMN1; SMN2KMT2A
SCHEMBL353277 0.78 KMT2A (0.36) HTTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL19119454 0.77 ALDH1A1 (0.33) HTTALDH1A1SMN1; SMN2KMT2ARAB9A
SCHEMBL352889 0.77 KMT2A (0.43) HTTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL353858 0.77 HTT (0.42) HTTALDH1A1SMN1; SMN2KMT2AMEN1
Phthalazinone SCHEMBL19118752 0.77 ALDH1A1 (0.35) HTTALDH1A1SMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA HTT 1843/4885AR 4316/4885ALDH1A1 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.